Eledon Pharmaceuticals(NASDAQ) ELDN

Eledon helps people who need organ transplants or suffer from nerve-wasting diseases. It creates medicines that stop the immune system from attacking new organs or nerves. These treatments aim to replace older drugs that can cause harmful side effects.

What Does Eledon Make?

• Tegoprubart: Lead antibody candidate designed to block specific immune signals that cause organ rejection or nerve damage.
• Kidney Program: Clinical trials focused on protecting new kidneys without using toxic drugs called calcineurin inhibitors; these are common transplant medicines.
• ALS Therapy: Investigational drug targeting inflammation in the brain and spinal cord to help patients with amyotrophic lateral sclerosis.
• Cell Transplants: Research into protecting transplanted islet cells to help people with type 1 diabetes manage blood sugar levels.

Strategic Moves and Partners

• Acquired Anelixis Therapeutics in September 2020 to secure the intellectual property rights for its lead drug candidate.
• Partnered with eGenesis in January 2023 to study xenotransplantation, which is the process of transplanting animal organs into humans.
• Prioritized kidney transplant research in January 2023 to focus resources on the most common type of solid organ transplant.
• Completed a Phase 2a clinical study for people living with ALS in May 2022 to evaluate safety and dosing.

What Makes the Science Unique

The company focuses on a molecule called CD40 Ligand to control immune cell activation without destroying those cells. This specific method aims to avoid the kidney damage and tremors often caused by standard transplant treatments used today.

Recent Financial Performance

• Net loss was $10.4 million in Q4 2025, narrowing and improving 76.6% from Q4 2024.
• Operating income reached a loss of $21.5 million in Q4 2025, narrowing and improving 13% from Q4 2024.
• Free cash flow was negative $14.1 million in Q4 2025, narrowing and improving 25.8% from Q4 2024.
• Total revenue remained at $0 in Q4 2025, which is typical for a biotechnology company in the testing phase.

Bottom Line

Eledon has evolved from a general ear and nose specialist into a focused developer of advanced transplant and nerve therapies. Its future depends on proving its lead drug can safely replace decades-old standards of care in hospitals worldwide.